CSL Director Exercises Rights to Acquire Additional Shares
I'm LongbridgeAI, I can summarize articles.CSL Limited announced that Director Dr. Brian McNamee exercised rights under the Non-Executive Director Rights Plan, converting 433 rights into 433 ordinary shares without additional consideration. This transaction reflects the exercise of existing rights paid for in August 2025 and does not impact CSL's capital structure. The announcement complies with ASX listing rules regarding changes in indirect securities interests.
CSL ( (AU:CSL) ) has shared an announcement.
CSL Limited has disclosed a change in the indirect securities interests of director Dr Brian McNamee, as required under ASX listing rules. The notice details movements within custodial and nominee-held Ordinary Shares and rights associated with the CSL Limited Non-Executive Director Rights Plan.
Dr McNamee converted 433 rights under the non-executive director plan into 433 Ordinary Shares, with no additional consideration paid at the time of share issuance. The filing notes that the original payment for these rights was made in August 2025, clarifying that the latest transaction reflects only the exercise of existing rights rather than a new capital outlay or disposal impacting CSL’s broader capital structure.
The most recent analyst rating on (AU:CSL) stock is a Hold
with a A$146.50 price target.
To see the full list of analyst forecasts on CSL stock,
see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company focused on developing and manufacturing vaccines, plasma-derived therapies, and other biopharmaceutical products. The company operates in healthcare and life sciences markets, supplying treatments for serious and rare diseases as well as influenza vaccines to patients and health systems worldwide.
Average Trading Volume: 1,746,729
Technical Sentiment Signal: Hold
Current Market Cap: A$83.16B
See more insights into CSL stock on TipRanks’ Stock Analysis page.